DOI:
10.1055/s-00000097
Deutsche Zeitschrift für Onkologie
LinksClose Window
References
Passalacqua R, Buzio C, Buti S, Labianca R, Porta C, Boni C, Rondini E, Camisa R, Sabbatini R, Artioli F, Caminiti C.
Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha
(IFN) in operable renal cell cancer (RCC). A phase III, randomized,
multicenter, independent trial of the Italian Oncology Group for Clinical
Research (GOIRC).
J Clin Oncol 2007; 25
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.